Capital Insight Partners LLC Has $2.40 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Capital Insight Partners LLC lessened its stake in Pfizer Inc. (NYSE:PFE) by 2.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 86,582 shares of the biopharmaceutical company’s stock after selling 2,580 shares during the quarter. Capital Insight Partners LLC’s holdings in Pfizer were worth $2,403,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Advisor OS LLC lifted its position in shares of Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after purchasing an additional 365 shares in the last quarter. Safeguard Investment Advisory Group LLC boosted its position in Pfizer by 3.9% during the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after purchasing an additional 371 shares during the last quarter. Lantz Financial LLC raised its stake in shares of Pfizer by 1.3% during the 1st quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock worth $849,000 after purchasing an additional 381 shares in the last quarter. King Wealth Management Group grew its stake in shares of Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 388 shares in the last quarter. Finally, Advance Capital Management Inc. raised its position in Pfizer by 4.0% during the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock worth $293,000 after acquiring an additional 391 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE opened at $27.99 on Friday. The firm has a market cap of $158.61 billion, a P/E ratio of -466.42, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The business’s fifty day moving average is $27.90 and its 200-day moving average is $27.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same period last year, the firm posted $1.23 earnings per share. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. Sell-side analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.00%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s dividend payout ratio is -2,799.53%.

Analysts Set New Price Targets

PFE has been the topic of a number of research analyst reports. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.